Dennis M. Lanfear - Jan 4, 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role: President & CEO, Director
Signature: /s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Stock symbol: CHRS
Transactions as of: Jan 4, 2023
Transactions value $: -$107,632
Form type: 4
Date filed: 1/6/2023, 05:17 PM
Previous filing: Jan 4, 2023
Next filing: Jan 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CHRS	Common Stock	Tax liability	-$108K	-10.9K	-1.88%	$9.87	569K	Jan 4, 2023	Direct	F1
holding	CHRS	Common Stock						433K	Jan 4, 2023	By Trust	F2
holding	CHRS	Common Stock						87K	Jan 4, 2023	By LLC	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CHRS	Stock Option (Right to Buy)	Award	$0	+403K		$0.00	403K	Jan 5, 2023	Common Stock	403K	$10.37	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3.
F2	These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F3	These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F4	The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.